The company
Ionis Pharmaceuticals, Inc.
IONS · Nasdaq
Health CareBiotechnologyNot moving yet
IONS stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 15 weeks. It is 31.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 15
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $2.1M
- Insider sales, 12 months
- $247.1M
- Officials’ trades on record
- 10
- Institutions holding
- 480 (+16)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.
20 Apr – 19 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
10 disclosed lines: House 9, Senate 1, executive 0; 4 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Daniel S. Goldman House: U.S. House ClerkNY10 | sold | $1k–$15k | 6 Mar 2023filed 17 Apr 2023 |
| Donna E. Shalala House: U.S. House ClerkFL27 | sold | $1k–$15k | 24 Jun 2019filed 27 Apr 2020 |
| Donna E. Shalala House: U.S. House ClerkFL27 | bought | $1k–$15k | 8 May 2019filed 27 Apr 2020 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | bought | $1k–$15k | 2 Nov 2016filed 2 Dec 2016 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | bought | $1k–$15k | 2 Nov 2016filed 2 Dec 2016 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | bought | $15k–$50k | 2 Nov 2016filed 2 Dec 2016 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | bought | $1k–$15k | 24 Feb 2016filed 3 Mar 2016 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | bought | $1k–$15k | 12 Feb 2016filed 3 Mar 2016 |
| Thomas MacArthur House: U.S. House ClerkNJ03 | sold | $15k–$50k | 2 Feb 2016filed 3 Mar 2016 |
| Sheldon Whitehouse Senate: U.S. Senate eFDSenator | sold | $1k–$15k | 20 Jan 2016filed 23 Feb 2016 |
Insiders
Buy orders, 12 months2
Sale orders, 12 months81
Buyers · sellers1 · 19
| Who | Did | Shares | Traded |
|---|---|---|---|
| Eric SwayzeEVP Research | sold | 53at $43.54 | 16 Oct 2026filed 19 Oct 2026 |
| Shannon L. DeversEVP, Chief Human Resources Ofc | sold | 1,357at $43.54 | 16 Oct 2026filed 19 Oct 2026 |
| Michael R. HaydenDirector | bought | 5,000at $51.60 | 31 Jul 2026filed 31 Jul 2026 |
| Michael R. HaydenDirector | bought | 15,000at $53.38 | 30 Jul 2026filed 31 Jul 2026 |
| Holly B. KordasiewiczEVP, Chief Development Officer | sold | 362at $84.30 | 7 Jul 2026filed 9 Jul 2026 |
| Allene M. DiazDirector | sold | 10,111at $85.42 | 7 Jul 2026filed 9 Jul 2026 |
| C. Frank BennettEVP, Chief Scientific Officer | sold | 5,536at $83.58 | 7 Jul 2026filed 9 Jul 2026 |
| C. Frank BennettEVP, Chief Scientific Officer | sold | 15,000at $85.46 | 7 Jul 2026filed 9 Jul 2026 |
| Joseph Klein IIIDirector | sold | 99at $79.45 | 1 Jul 2026filed 6 Jul 2026 |
| Joseph Klein IIIDirector | sold | 11,419at $79.04 | 1 Jul 2026filed 6 Jul 2026 |
| Brett P. MoniaChief Executive Officer | sold | 50,000at $80.59 | 26 Jun 2026filed 26 Jun 2026 |
| Eugene SchneiderEVP, Chf Clinical Develop Ofcr | sold | 26,000at $81.05 | 26 Jun 2026filed 30 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders480+16 on the quarter
New · exited62 · 47
Reported value$13.6B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 24,631,956$2.0B | +75,319+0.3% |
| Capital World Investorsadded · filed 12 Aug 2026 | 21,669,226$1.7B | +482,857+2.3% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 10,704,660$848.8M | +262,184+2.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 7,859,529$623.2M | +50,627+0.6% |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 7,651,415$606.7M | +1,259,599+19.7% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 7,211,497$571.8M | +93,167+1.3% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 6,252,342$495.7M | +394,713+6.7% |
| ROYAL BANK OF CANADAadded · filed 14 Aug 2026 | 6,182,479$490.2M | +2,380,664+62.6% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,334,848$343.7M | +339,284+8.5% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 3,584,024$294.8M | -400,308−10.0% |
31 Mar 2023 – 30 Jun 2026
News
Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)finanznachrichten.de · 16 Oct 2026Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlookaol.com · 20 Sep 2026Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.aol.com · 9 Sep 2026Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpointyahoo.com · 8 Sep 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.